1973 - the parent company was founded.

2008 - Raybow was founded as the CDMO unit of the parent company.

2014 - the parent company was listed on Shanghai Stock Exchange (Jiuzhou Pharma, stock ticker:603456).

2019 - previous NMC pharma API manufacturing site in Suzhou China was acquired and renamed as "Raybow Suzhou".

2019 - previous PharmAgra Labs in Brevard NC was acquired and renamed as "Raybow USA".

2019 - Raybow's CDMO business revenue from European and US clients passed USD 100 million.

2022 - Raybow's global CDMO service revenue passed USD 500 million.

2023 - previous NMC formulation manufacturing site in Zhongshan China was acquired and renamed as "Rayhua Zhongshan".